ATE175446T1 - Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung - Google Patents

Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung

Info

Publication number
ATE175446T1
ATE175446T1 AT91911895T AT91911895T ATE175446T1 AT E175446 T1 ATE175446 T1 AT E175446T1 AT 91911895 T AT91911895 T AT 91911895T AT 91911895 T AT91911895 T AT 91911895T AT E175446 T1 ATE175446 T1 AT E175446T1
Authority
AT
Austria
Prior art keywords
antibodies
connection
immunogenic peptides
receptor binding
disclosed
Prior art date
Application number
AT91911895T
Other languages
English (en)
Inventor
Joseph G Sodroski
William A Haseltine
Udy Olshevsky
Eirik Hleseth
Craig D Furman
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE175446T1 publication Critical patent/ATE175446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91911895T 1990-05-16 1991-05-16 Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung ATE175446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52463290A 1990-05-16 1990-05-16
US66907291A 1991-03-14 1991-03-14

Publications (1)

Publication Number Publication Date
ATE175446T1 true ATE175446T1 (de) 1999-01-15

Family

ID=27061560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91911895T ATE175446T1 (de) 1990-05-16 1991-05-16 Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung

Country Status (7)

Country Link
US (2) US5817316A (de)
EP (1) EP0651818B1 (de)
JP (1) JPH05507491A (de)
AT (1) ATE175446T1 (de)
CA (1) CA2082948C (de)
DE (1) DE69130741T2 (de)
WO (1) WO1991017764A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554401A4 (en) * 1990-10-26 1996-10-30 New York Health Res Inst Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
JPH05262662A (ja) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Ｈｉｖ重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法
WO1994004574A1 (en) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
EP0581353A1 (de) * 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6908617B1 (en) 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
WO1999024464A1 (en) 1997-11-10 1999-05-20 Dana-Farber Cancer Institute, Inc Glycosylated modified primate lentivirus envelope polypeptides
US6679851B2 (en) * 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US7585839B2 (en) * 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
CA2431212A1 (en) * 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
JP2006504435A (ja) * 2002-05-10 2006-02-09 ザ ヘンリー エム． ジャクソン ファウンデイション ＨＩＶ−１のｇｐ１２０のｇｐ４１への相互作用部位
JP3849584B2 (ja) * 2002-06-07 2006-11-22 トヨタ自動車株式会社 蒸発燃料処理装置
WO2004110384A2 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
CA2539452C (en) * 2003-09-17 2013-10-29 Guava Technologies, Inc. Compositions and methods for analysis of target analytes
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators
CN107141353A (zh) 2009-03-05 2017-09-08 哈佛学院董事会 分泌的aP2及其抑制方法
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2492279A1 (de) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Also Published As

Publication number Publication date
CA2082948A1 (en) 1991-11-17
US5858366A (en) 1999-01-12
WO1991017764A1 (en) 1991-11-28
US5817316A (en) 1998-10-06
JPH05507491A (ja) 1993-10-28
EP0651818A1 (de) 1995-05-10
CA2082948C (en) 2000-07-11
EP0651818A4 (de) 1993-08-09
DE69130741D1 (de) 1999-02-18
EP0651818B1 (de) 1999-01-07
DE69130741T2 (de) 1999-07-29

Similar Documents

Publication Publication Date Title
DE69130741D1 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
EP0434713A4 (en) Hiv-1 envelope muteins lacking hypervariable domains
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
CZ105795A3 (en) Pharmaceutical preparation containing antagonists of vascular endothelial cell growth factor
CA2290485A1 (en) Method for the production of non-immunogenic proteins
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
AU1986588A (en) Growth hormone receptor
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
DE69632815D1 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
AU7565991A (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
FR2669338B1 (de)
IL127595A (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
TR199800912T2 (xx) T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.
DE69434384D1 (de) Metalkomplexbildner
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
DE59813388D1 (de) Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
NO923415L (no) Forbedrede chimere toksiner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties